title: Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice.
abstract: OBJECTIVE
  To study the inhibitory effect of oxymatrine on serum hepatitis B virus (HBV) DNA in HBV transgenic mice.
  
  
  METHODS
  HBV transgenic mice model was established by microinjection, and identified by HBV DNA integration and replication. Transgenic mice with replicating HBV were divided into 3 groups, and injected with normal saline (group A, n=9), 50 mg/kg (group B, n=8) and 100 mg/kg (group C, n=9) oxymatrine intraperitoneally once a day for 30 d, respectively. Quantitation of serum HBV DNA in HBV transgenic mice was performed by competitive polymerase chain reaction (PCR) in combination with DNA hybridization quantitative detection technique before and after treatment.
  
  
  RESULTS
  Compared with pre-treatment, the serum HBV DNA in group A (F=1.04, P=0.9612) and group B (F=1.13, P=0.8739) had no changes after treatment. However, in group C serum HBV DNA was significantly decreased (F=13.97, P=0.0012). The serum HBV DNA after treatment was lower in group C than in groups B and A (F=8.65, P=0.0068; F=12.35, P=0.0018; respectively). The serum HBV DNA after treatment was lower in group B than in group A, but there was no statistical significance (F=1.43, P=0.652).
  
  
  CONCLUSIONS
  Oxymatrine has inhibitory effects on serum HBV DNA in HBV transgenic mice.
authors.affiliation: Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China. lulungen@online.sh.cn
authors.forename: Lun-Gen
authors.initials: LG
authors.lastname: Lu
authors.forename: Min-De
authors.initials: MD
authors.lastname: Zeng
authors.forename: Yi-Min
authors.initials: YM
authors.lastname: Mao
authors.forename: Jing-Yuan
authors.initials: JY
authors.lastname: Fang
authors.forename: Yu-Lin
authors.initials: YL
authors.lastname: Song
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Shen
authors.forename: Ai-Ping
authors.initials: AP
authors.lastname: Cao
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics* / Q000254:growth & development; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D051379:Mice; D008813:Mice, Inbred ICR; D008822:Mice, Transgenic; D011807:Quinolizines; D016662:Virus Integration / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000998:Antiviral Agents; D004279:DNA, Viral; D011807:Quinolizines; C037573:oxymatrine; D000093842:Matrines